Publication of a New Study on Voluntis by Brokerage Firm Bryan, Garnier & Co
CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Regulatory News:
Voluntis (Paris:ALVTX) (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960), a leader in the field of digital therapeutics, announces that Bryan, Garnier & Co, a leading pan-European investment bank dedicated to growth companies, has just updated its coverage of the company in a study entitled “A front-runner in Digital Therapeutics”.
The publication of this new study is in line with the objective of increasing Voluntis’ visibility, broadening its investor base and updating the consensus of financial analysts who follow the stock alongside brokerage firm Gilbert Dupont.
The executive summary of Bryan, Garnier & Co analysis note is available via the following…